Display options
Cite
Djanani A, Mosheimer B, Kaneider NC, et al. Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin. J Inflamm (Lond). 2006;3:14doi: 10.1186/1476-9255-3-14.
Djanani, A., Mosheimer, B., Kaneider, N. C., Ross, C. R., Ricevuti, G., Patsch, J. R., & Wiedermann, C. J. (2006). Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin. Journal of inflammation (London, England), 314. https://doi.org/10.1186/1476-9255-3-14
Djanani, Angela, et al. "Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin." Journal of inflammation (London, England) vol. 3 (2006): 14. doi: https://doi.org/10.1186/1476-9255-3-14
Djanani A, Mosheimer B, Kaneider NC, Ross CR, Ricevuti G, Patsch JR, Wiedermann CJ. Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin. J Inflamm (Lond). 2006 Nov 02;3:14. doi: 10.1186/1476-9255-3-14. PMID: 17081280; PMCID: PMC1635031.
Copy Download .nbib Format: NLM
Share it on

J Inflamm (Lond). 2006 Nov 02;3:14. doi: 10.1186/1476-9255-3-14.

Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin.

Journal of inflammation (London, England)

Angela Djanani, Birgit Mosheimer, Nicole C Kaneider, Christopher R Ross, Giovanni Ricevuti, Josef R Patsch, Christian J Wiedermann

Affiliations

  1. Laboratory of Medical Intensive Care, Division of General Internal Medicine, Department of Medicine, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. [email protected]

PMID: 17081280 PMCID: PMC1635031 DOI: 10.1186/1476-9255-3-14

Abstract

Cathelicidins are mammalian proteins containing a C-terminal cationic antimicrobial domain. Porcine PR-39 cathelicidin affects leukocyte biology. Mechanisms of action may involve alteration of heparan sulfate proteoglycan-dependent functions in inflammatory cells. It was tested whether PR-39 affects human neutrophil migration and if such effects involve heparan sulphate proteoglycans. Neutrophils were from forearm venous blood of healthy donors. Migration was tested in modified Boyden chamber assays. Involvement of heparan sulfate proteoglycans was tested by their chemical modification and by the use of specific antibodies. PR-39 induced migration in neutrophils in a concentration dependent manner. Modification of heparan sulfate proteoglycans with sodium chlorate inhibited migration whereas chemotaxis toward the chemoattractant formyl-Met-Leu-Phe was not affected. Removal of heparan sulfates or chondroitin sulfates from the surface of neutrophils by heparinase or chondroitinase inhibited migration toward PR-39. In conclusion, antimicrobial PR-39 stimulates human neutrophil chemotaxis in a heparan sulfate proteoglycan-dependent manner. Involvement of syndecans is likely as both heparinase and chondroitinase were abrogating. Data suggest active participation of heparan sulfate proteoglycans of neutrophils in cathelicidin peptide-mediated regulation of the antimicrobial host defense.

References

  1. Infect Immun. 1999 May;67(5):2561-6 - PubMed
  2. J Med Microbiol. 1999 Mar;48(3):223-33 - PubMed
  3. Biochem Biophys Res Commun. 1999 Aug 19;262(1):25-30 - PubMed
  4. Br J Cancer. 1999 Oct;81(3):393-403 - PubMed
  5. Nat Med. 2000 Jan;6(1):49-55 - PubMed
  6. J Cell Physiol. 1993 Nov;157(2):413-25 - PubMed
  7. FEBS Lett. 1994 Jan 17;337(3):303-7 - PubMed
  8. J Cell Biol. 1993 Aug;122(4):941-50 - PubMed
  9. J Biol Chem. 1993 Jan 5;268(1):522-6 - PubMed
  10. Infect Immun. 1993 Jul;61(7):2978-84 - PubMed
  11. Antimicrob Agents Chemother. 1996 Jan;40(1):115-21 - PubMed
  12. J Leukoc Biol. 1997 May;61(5):624-9 - PubMed
  13. J Biol Chem. 1997 May 16;272(20):13088-93 - PubMed
  14. Blood. 1997 Oct 1;90(7):2796-803 - PubMed
  15. J Cell Biol. 1998 Jan 12;140(1):211-21 - PubMed
  16. J Clin Invest. 1998 Feb 15;101(4):877-89 - PubMed
  17. J Biol Chem. 1998 Oct 30;273(44):28978-85 - PubMed
  18. Annu Rev Biochem. 1999;68:729-77 - PubMed
  19. J Exp Med. 2000 Oct 2;192(7):1069-74 - PubMed
  20. Blood. 2001 Feb 15;97(4):1079-85 - PubMed
  21. Biochem Biophys Res Commun. 2001 Sep 14;287(1):42-6 - PubMed
  22. Curr Opin Hematol. 2002 Jan;9(1):18-22 - PubMed
  23. Curr Opin Immunol. 2002 Feb;14(1):96-102 - PubMed
  24. Immunology. 2002 May;106(1):20-6 - PubMed
  25. J Biol Chem. 2002 Sep 6;277(36):32970-7 - PubMed
  26. J Mol Med (Berl). 2002 Sep;80(9):549-61 - PubMed
  27. Biochim Biophys Acta. 2002 Dec 12;1588(3):232-40 - PubMed
  28. Annu Rev Cell Biol. 1992;8:365-93 - PubMed
  29. J Biol Chem. 1992 Oct 5;267(28):20435-43 - PubMed
  30. Adv Exp Med Biol. 2003;530:645-52 - PubMed
  31. Eur J Biochem. 2004 Mar;271(6):1219-26 - PubMed
  32. Eur J Biochem. 1991 Dec 18;202(3):849-54 - PubMed
  33. Annu Rev Biochem. 1991;60:443-75 - PubMed
  34. J Cell Biol. 1990 Oct;111(4):1363-71 - PubMed
  35. Arteriosclerosis. 1989 Jan-Feb;9(1):21-32 - PubMed
  36. Blood. 1983 Feb;61(2):257-66 - PubMed
  37. FEBS Lett. 1995 Dec 4;376(3):225-8 - PubMed
  38. Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):195-9 - PubMed
  39. FEBS Lett. 1995 Oct 23;374(1):1-5 - PubMed
  40. Eur J Biochem. 1995 Mar 15;228(3):941-6 - PubMed
  41. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11035-9 - PubMed
  42. J Leukoc Biol. 1994 Dec;56(6):807-11 - PubMed

Publication Types